Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis.
Plasmacytoid dendritic cells (pDCs) represent a DC subtype that exerts divergent functions in innate and adoptive immunity including the immediate reaction to microbial factors and the induction of immunoregulatory responses. It is thought that different DC subtypes may be critically involved in the pathogenesis of multiple sclerosis (MS). In our study we assessed the phenotype, maturation and functional properties of peripheral blood pDCs from 35 clinically stable, untreated multiple sclerosis patients, 30 healthy controls and 9 patients with pneumonia, which was used as a non-specific inflammatory condition (NIC). Ex vivo expression of CD86 and 4-1BBL was significantly lower on pDCs from multiple sclerosis patients than from controls and patients with NIC (22 versus 47 versus 41% and 12 versus 35 versus 32%, respectively). When stimulated with IL-3 and CD40L, pDCs of multiple sclerosis patients showed inefficient maturation as demonstrated by significantly lower or delayed upregulation of CD86, 4-1BBL, CD40 and CD83. Additionally, in multiple sclerosis, stimulation of pDCs by unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides (CpG ODN) resulted in a significantly lower interferon (IFN) alpha secretion than in controls. In multiple sclerosis, but not in controls, pDCs failed to upregulate proliferative responses and IFN-gamma secretion of autologous peripheral blood mononuclear cells (PBMC) in a co-culture system. Moreover, depletion of pDCs in multiple sclerosis patients, but not in controls, had no effect on generation of CD4+Foxp3+ regulatory T cells. We also provide data showing that glatiramer acetate (GA) treatment partially restores phenotype and function of pDCs in multiple sclerosis patients. These findings suggest functional abnormalities of pDCs in these patients, which might be of importance in the understanding of the development of immune dysregulation in this disease.
Stasiolek
Mariusz
M
Department of Neurology, Medical University of Lodz, Lodz, Poland.
Bayas
Antonios
A
Kruse
Niels
N
Wieczarkowiecz
Anja
A
Toyka
Klaus V
KV
Gold
Ralf
R
Selmaj
Krzysztof
K
D015703:Antigens, CD / Q000097:blood; D002454:Cell Differentiation; D049109:Cell Proliferation; D002478:Cells, Cultured; D018920:Coculture Techniques; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology* / Q000502:physiology; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000494:pharmacology; D016898:Interferon-alpha / Q000096:biosynthesis; D007937:Leukapheresis; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000276:immunology*; D009838:Oligodeoxyribonucleotides / Q000276:immunology; D010455:Peptides / Q000494:pharmacology
D015703:Antigens, CD; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D009838:Oligodeoxyribonucleotides; D010455:Peptides; D000068717:Glatiramer Acetate